Glaukos Corporation
26061 Merit Circle
Suite 101
Laguna Hills
California
92653
United States
Tel: 949-367-9600
219 articles about Glaukos Corporation
-
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
4/21/2022
Glaukos Corporation announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 22–26, 2022 in Washington, D.C.
-
Glaukos Announces the Release of its 2021 Sustainability Report
4/20/2022
Glaukos Corporation today announced that it has published its 2021 Sustainability Report.
-
Glaukos to Release First Quarter 2022 Financial Results after Market Close on May 4
4/13/2022
Glaukos Corporation plans to release first quarter 2022 financial results after the market close on Wednesday, May 4, 2022.
-
Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink™ Therapy
3/14/2022
Glaukos Announces Commencement of Phase 2 Corneal Health Clinical Program for Third-Generation iLink ™ Therapy.
-
Glaukos Corporation Announces Fourth Quarter and Full Year 2021 Financial Results
2/22/2022
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the fourth quarter and full year ended December 31, 2021.
-
Glaukos Announces Executive Leadership Changes
2/7/2022
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced several executive leadership changes to support the company’s future growth and strategic plans.
-
Glaukos’ iDose® TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 36 Months in Phase 2b Study
1/11/2022
Glaukos Corporation (NYSE: GKOS), today announced that its iDose® TR sustained-release travoprost implant continued to provide sustained substantial reductions in intraocular pressure (IOP) in a 36-month analysis of the 36-month Phase 2b clinical trial conducted under a U.S. Investigational New Drug (IND) protocol.
-
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Presbyopia
1/11/2022
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-302 for the treatment of presbyopia.
-
Glaukos Announces First Patient Enrolled in Phase 2 Clinical Trial for Dry Eye Disease
1/11/2022
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has enrolled the first patient into a Phase 2 clinical trial of GLK-301 for the treatment of signs and symptoms of Dry Eye Disease (DED).
-
Glaukos Announces FDA 510(k) Clearance of iPRIME™
1/6/2022
Glaukos Corporation (NYSE: GKOS), today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the iPRIME™ Viscodelivery System, a sterile, single-use, minimally-invasive device for the delivery of viscoelastic fluid during ophthalmic surgery.
-
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
12/29/2021
Glaukos Corporation today announced that its management is scheduled to virtually participate in the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022, at 5:15 p.m. ET.
-
Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director
12/20/2021
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021.
-
Glaukos Announces Participation in Upcoming Investor Conferences - Nov 19, 2021
11/19/2021
Glaukos Corporation announced that its management is scheduled to virtually participate in the following upcoming investor conferences
-
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 American Academy of Ophthalmology Annual Meeting
11/11/2021
Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be highlighted in various scientific programming at the American Academy of Ophthalmology (AAO) annual meeting, being held November 12–15, 2021 in New Orleans, Louisiana.
-
Glaukos Corporation Announces Third Quarter 2021 Financial Results
11/4/2021
Glaukos Corporation today announced financial results for the third quarter ended September 30, 2021.
-
Glaukos Corporation to Release Third Quarter 2021 Financial Results after Market Close on November 4
10/14/2021
Glaukos Corporation plans to release third quarter 2021 financial results after the market close on Thursday, November 4, 2021.
-
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2021 European Society of Cataract and Refractive Surgeons Annual Meeting
10/7/2021
Glaukos Corporation announced that its technologies will be featured in various scientific programming at the European Society of Cataract and Refractive Surgeons Annual Meeting, being held October 8-11, 2021, in Amsterdam, Netherlands.
-
Glaukos Announces Licensing Agreement with Attillaps Holdings, Inc.
9/20/2021
Glaukos Corporation announced today that it has entered into a licensing agreement with Attillaps Holdings, Inc.
-
Glaukos Announces Settlement of Patent Litigation with Ivantis, Inc.
9/15/2021
Ivantis to Pay $60 Million and Ongoing Double-Digit Royalty to Glaukos
-
Glaukos Announces Submission of Supplemental Pre-Market Approval Application for iStent infinite™
9/3/2021
Glaukos Corporation (NYSE: GKOS), today announced that it has submitted a supplemental pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA) for the iStent infinite™ Trabecular Micro-Bypass System.